Contact
searchSearch
HMP Global
Login

Metastatic Colorectal Cancer Specialty Channel

Metastatic Colorectal Cancer
Specialty Channel
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
Conference Coverage
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
Quiz
Oxaliplatin-Based Chemotherapy and Targeted Agents for Metastatic Colorectal Cancer
11/24/2025
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors...
11/24/2025
Oncology

News

News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
Conference Coverage
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
News
Eribulin Demonstrates Limited Efficacy in BRAF V600E-Mutated Metastatic Colorectal Cancer
11/04/2025
Stephanie Holland
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY...
11/04/2025
Oncology

Interactive Features

Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Oxaliplatin-Based Chemotherapy and Targeted Agents for Metastatic Colorectal Cancer
11/24/2025
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors was identified as prognostic for OS and PFS in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy plus molecular targeted agents?
Which of the following factors...
11/24/2025
Oncology
Quiz
Adding Bevacizumab to Trifluridine and Tipiracil for Previously Treated Patients With Metastatic Colorectal Cancer
09/30/2025
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis results from the phase 3 SUNLIGHT trial, did the addition of bevacizumab to trifluridine and tipiracil improve tumor response among previously treated patients with metastatic colorectal cancer? Take our quiz to...
Based on post hoc analysis...
09/30/2025
Oncology
Quiz
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
08/05/2025
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to updated results from the OrigAMI-1 trial, amivantamab rechallenge showed promising antitumor activity and lengthened survival end points among patients with left-sided metastatic colorectal cancer who underwent...
True or False: According to...
08/05/2025
Oncology
Quiz
Sotorasib Plus Panitumumab and FOLFIRI for Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
07/23/2025
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to results from the phase 1b CodeBreaK 101 study, sotorasib plus panitumumab and FOLFIRI demonstrated long-term efficacy and safety among patients with KRAS G12C-mutated metastatic colorectal cancer.
True or False: According to...
07/23/2025
Oncology

Recent News

News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
Conference Coverage
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
News
CMS4 Identified as Potential Biomarker of Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/16/2025
Stephanie Holland
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an individual patient data meta-analysis, CMS4 may serve as a predictive biomarker for improved outcomes with anti-EGFR therapy among patients with RAS and BRAF wild-type metastatic colorectal cancer.
According to results from an...
12/16/2025
Oncology
News
Plasma Tie2 Predicts Bevacizumab Response in Patients With Metastatic Colorectal Cancer
12/03/2025
Stephanie Holland
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the phase 2 TRAVASTIN study reinforce plasma Tie2 as a meaningful vascular response biomarker for bevacizumab among patients with metastatic colorectal cancer (mCRC).
New long-term data from the...
12/03/2025
Oncology
News
Panitumumab Retreatment Improves Outcomes in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
11/12/2025
Stephanie Holland
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed improved response and disease control compared to regorafenib among patients with chemorefractory RAS and BRAF wild-type metastatic colorectal cancer who exhibited no mutations of resistance in ctDNA.
Panitumumab retreatment showed...
11/12/2025
Oncology
News
Eribulin Demonstrates Limited Efficacy in BRAF V600E-Mutated Metastatic Colorectal Cancer
11/04/2025
Stephanie Holland
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY trial show that eribulin demonstrates limited efficacy in previously treated patients with BRAF V600E-mutated metastatic colorectal cancer.
Results from the phase 2 BRAVERY...
11/04/2025
Oncology
News
Panitumumab Plus Regorafenib Treatment Sequence Did Not Significantly Impact Survival in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
10/29/2025
Stephanie Holland
Final results from the phase 2 PARERE study demonstrate that the treatment sequence of panitumumab plus regorafenib did not significantly impact overall survival results among patients with RAS and BRAF wild-type metastatic colorectal cancer.
Final results from the phase 2 PARERE study demonstrate that the treatment sequence of panitumumab plus regorafenib did not significantly impact overall survival results among patients with RAS and BRAF wild-type metastatic colorectal cancer.
Final results from the phase 2...
10/29/2025
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use